Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
118 hedge funds and large institutions have $666M invested in Accelerate Diagnostics in 2017 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 29 increasing their positions, 38 reducing their positions, and 24 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
10% more capital invested
Capital invested by funds: $605M → $666M (+$61.4M)
0% more funds holding
Funds holding: 118 → 118 (0)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
18% less call options, than puts
Call options by funds: $15.2M | Put options by funds: $18.5M
24% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.92M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.5M |
| 3 |
AG
Artal Group
Luxembourg
|
+$7.03M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.78M |
| 5 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$4.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$23.3M |
| 2 |
MGM
Miura Global Management
New York
|
-$15.5M |
| 3 |
O
OppenheimerFunds
New York
|
-$5.95M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.43M |
| 5 |
Credit Agricole
Montrouge Cedex,
France
|
-$4.23M |
AXDX Hedge Fund Activity: Q4 2017 in Review
118 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2017, worth a combined $666M — up 10% from $605M a quarter earlier.
Fund positioning in AXDX was balanced in Q4 2017: 24 funds opened new positions, 24 closed out, 29 added to existing stakes and 38 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $8.92M. The largest seller was Polar Capital, exiting entirely with an estimated $23.3M sold.
- 118 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $666M of Accelerate Diagnostics stock for Q4 2017, up 10% quarter-over-quarter.
- 24 funds opened new Accelerate Diagnostics positions in Q4 2017 and 24 closed out, a net change of 0 holders.
- The largest Accelerate Diagnostics buyer in Q4 2017 was Balyasny Asset Management, an estimated $8.92M added.
- The largest Accelerate Diagnostics seller in Q4 2017 was Polar Capital, an estimated $23.3M sold.
Based on aggregated 13F filings for Q4 2017.